Dedicated to Significant Progress
At Astellas, our commitment to R&D is based on the development of first-in-class
and best-in-class products in our therapeutic areas of focus. In the U.S., Astellas
has a robust pipeline of products in clinical development, which is supported through
- Focus on research and development in key therapeutic areas,
infectious disease, oncology and
urology. Within each therapeutic area, Astellas focuses on unsurpassed science
and building networks of trust among physicians, patients and our partners.
- Commitment to discovering and developing innovative therapies
that address unmet medical needs in areas such as oncology. Agensys, Inc., a
subsidiary of Astellas Pharma Inc. is developing a pipeline of therapeutic fully
human monoclonal antibodies (MAbs) to treat solid tumor cancers. Agensys is furthering
a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies,
directed at a variety of cancer indications, including those of the prostate, kidney,
pancreas, ovary, bladder, lung, colon, breast, and skin.
- Ability to maximize our broad research network to research
and develop innovative drugs. At Astellas, we are committed to discovering novel
biological targets and new chemical entities with unique mechanisms. We are able
to pursue a wide range of leads for innovative drugs, including chemical compounds,
natural substances, and proteins created by genomic technologies, through the full
range of state-of-the-art technologies.
- Dedication to growing our highly focused, efficient and scientifically
meaningful development program. Clinical studies that benefit our global development
program are conducted at our headquarters for the Americas located in Northbrook,
Illinois. In 2008, Astellas relocated its Astellas Pharma Global Development headquarters
from Japan to the United States.
For more information about our global research and development capabilities, please
Astellas Pharma Inc., Web site.